Share this article and save a life!
The mammogram that tells your future just got FDA approval.
In 2025, we crossed a remarkable threshold. The FDA authorized Clairity Breast, the first AI system that predicts your five-year breast cancer risk from a single standard mammogram.
No family history questionnaires.
No genetic testing.
Just the imaging data you’re already collecting.
Think about what this means:
📊 Every routine screening becomes a risk assessment
🎯 High-risk women get identified for enhanced screening
⏰ Prevention strategies start years before cancer develops
💡 Health equity improves (no literacy barriers from questionnaires)
The technology was validated on hundreds of thousands of mammograms. It doesn’t just detect existing cancer, it predicts future risk based on subtle tissue patterns invisible to human eyes.
Here’s the game changer:
We screen 40 million women annually for breast cancer. Until now, most received the same one-size-fits-all protocol. This AI enables truly personalized screening intervals, supplemental imaging decisions, and prevention conversations.
But here’s my concern:
Will insurance cover risk-based screening protocols? Will health systems invest in the infrastructure? Will radiologists embrace predictive, not just diagnostic, roles?
We have the technology to prevent thousands of late-stage diagnoses. The FDA opened the door. Now healthcare leaders must walk through it.
The future of cancer screening isn’t finding disease.
It’s preventing it from happening.
♻️ Repost if personalized cancer prevention should be standard care.
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
